YH-0623

YH-0623 reduces the ND1 mitochondrial factor to 14%, exhibits antiproliferative activity on 22Rv1, C42B, VCap, LNCap, MDA-PCa-2b cells, with IC₅₀s of 0.045, 0.64, 1.988, 1.941 μM, exhibits minimal cytotoxicity to WPMY-1 cells, with an IC₅₀ > 100 μM^[1].
YH-0623 (1-500 nM) inhibits mitochondrial transcription and mitochondrial-related gene expression in 22Rv1 cells, resulting in reduced expression of mtDNA-encoded OXPHOS proteins while preserving expression of nuclear-encoded proteins^[1].
YH-0623 (1 μM, 12 h) accumulates in mitochondria at a concentration of 767.07 ng/mg/protein in 22Rv1 cells^[1].
YH-0623 (50-500 nM, 96 h) inhibits mitochondrial function primarily by suppressing OXPHOS without significantly altering MMP, ROS levels, or glycolytic activity in 22Rv1 cells^[1].
YH-0623 (10 μM, 96 h) displays inhibitory effect against PDGFRα (IC₅₀ ≈ 10 μM), achieving an inhibition rate of 55.97%^[1].
YH-0623 leads to a significant decrease in the levels of several key amino acids, including L-Leucine, L-Valine, L-Alanine, L-Glutamine, L-Isoleucine, L-Aspartic acid, L-Tyrosine, L-Phenylalanine, Phosphorylcholine, L-Lysine, Choline, and L-Threonine, decreases amino acids, causes severe nutrient depletion in 22Rv1 cells^[1].
YH-0623 (0.3-30 μM) exhibits minimal hERG channel inhibition (IC₅₀ = 30 μM), suggesting a low potential for cardiac toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.